Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors

NCT06751329 is registered in ClinicalTrials.gov with Xadcera Biopharmaceutical (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT06751329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06751329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors
Lead sponsor
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 17, 2025
Completion date
April 18, 2028
Enrollment
280 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms, endometrial neoplasms, ovarian neoplasms, pancreatic cancer, prostatic neoplasms, solid carcinoma